Shuguang Tan

List of Publications by Year
in descending order

54 papers	5,358 citations	186209 28 h-index	161767 54 g-index
56 all docs	56 docs citations	56 times ranked	11733 citing authors

#	ARTICLE	IF	CITATIONS
1	An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nature Immunology, 2022, 23, 423-430.	7.0	38
2	Avian influenza viruses suppress innate immunity by inducing trans-transcriptional readthrough via SSU72. , 2022, 19, 702-714.		5
3	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy. Frontiers in Immunology, 2022, 13, 826045.	2.2	13
4	Pneumonia Severity and Phase Linked to Virus-Specific T Cell Responses with Distinct Immune Checkpoints during pH1N1 Infection. Journal of Immunology, 2022, , ji2101021.	0.4	0
5	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Communications, 2021, 12, 776.	5.8	65
6	Identification of NY-ESO-1157–165 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy. Frontiers in Immunology, 2021, 12, 644520.	2.2	8
7	Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. Cell, 2021, 184, 3438-3451.e10.	13.5	100
8	Atypical TNF-TNFR superfamily binding interface in the GITR-GITRL complex for T cell activation. Cell Reports, 2021, 36, 109734.	2.9	3
9	Cross-species recognition of SARS-CoV-2 to bat ACE2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	73
10	Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. International Journal of Biological Sciences, 2021, 17, 4073-4091.	2.6	31
11	Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cellular and Molecular Immunology, 2020, 17, 966-975.	4.8	38
12	Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses. Nature Communications, 2020, 11, 5964.	5.8	22
13	Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy. Signal Transduction and Targeted Therapy, 2020, 5, 158.	7.1	8
14	N–glycosylation of PD–1 promotes binding of camrelizumab. EMBO Reports, 2020, 21, e51444.	2.0	47
15	A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science, 2020, 368, 1274-1278.	6.0	964
16	Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerging Microbes and Infections, 2020, 9, 1238-1241.	3.0	26
17	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6640-6650.	3.3	141
18	The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination. Signal Transduction and Targeted Therapy, 2020, 5, 16.	7.1	29

#	Article	IF	Citations
19	Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. National Science Review, 2020, 7, 1003-1011.	4.6	202
20	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences, 2020, 63, 364-374.	2.3	1,606
21	Clinical and Immunological Characteristics of Human Infections With H5N6 Avian Influenza Virus. Clinical Infectious Diseases, 2019, 68, 1100-1109.	2.9	56
22	Comparison between human infections caused by highly and low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and virological findings. Journal of Infection, 2019, 78, 241-248.	1.7	31
23	Molecular Basis of Arthritogenic Alphavirus Receptor MXRA8 Binding to Chikungunya Virus Envelope Protein. Cell, 2019, 177, 1714-1724.e12.	13.5	75
24	The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. IScience, 2019, 14, 113-124.	1.9	34
25	Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 988-996.	3.3	25
26	Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs, 2019, 11, 681-690.	2.6	30
27	Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein and Cell, 2018, 9, 135-139.	4.8	107
28	Clinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by Acinetobacter Baumannii: a case control study. BMC Infectious Diseases, 2018, 18, 664.	1.3	8
29	Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. Cell Reports, 2018, 25, 909-920.e4.	2.9	33
30	Prolonged Evolution of Virus-Specific Memory T Cell Immunity after Severe Avian Influenza A (H7N9) Virus Infection. Journal of Virology, 2018, 92, .	1.5	25
31	Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses. MBio, 2018, 9, .	1.8	25
32	The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	40
33	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications, 2017, 8, 14369.	5.8	192
34	CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection. Tuberculosis, 2017, 107, 5-12.	0.8	5
35	CD8 +T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection. Journal of Virology, 2017, 91, .	1.5	102
36	Hemagglutinin-specific CD4 + T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine, 2017, 35, 5644-5652.	1.7	10

#	Article	IF	Citations
37	Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Research, 2017, 27, 151-153.	5.7	116
38	Two classes of protective antibodies against Pseudorabies virus variant glycoprotein B: Implications for vaccine design. PLoS Pathogens, 2017, 13, e1006777.	2.1	34
39	Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget, 2017, 8, 67129-67139.	0.8	65
40	Nosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic Disorders. Emerging Infectious Diseases, 2016, 22, 598-607.	2.0	23
41	Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduction and Targeted Therapy, 2016, 1, 16029.	7.1	53
42	Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. Journal of Infectious Diseases, 2016, 214, 1937-1946.	1.9	24
43	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	4.8	44
44	The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. Scientific Reports, 2015, 5, 10942.	1.6	93
45	Nanozyme-strip for rapid local diagnosis of Ebola. Biosensors and Bioelectronics, 2015, 74, 134-141.	5.3	320
46	Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nature Communications, 2014, 5, 3595.	5.8	137
47	Conserved epitopes dominate cross‐CD8$^+$T‐cell responses against influenza A H1N1 virus among Asian populations. European Journal of Immunology, 2013, 43, 2055-2069.	1.6	37
48	Structural basis for the differential classification of HLA-A*6802 and HLA-A*6801 into the A2 and A3 supertypes. Molecular Immunology, 2013, 55, 381-392.	1.0	20
49	VP2 Dominated CD4+ T Cell Responses against Enterovirus 71 and Cross-Reactivity against Coxsackievirus A16 and Polioviruses in a Healthy Population. Journal of Immunology, 2013, 191, 1637-1647.	0.4	21
50	Cross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive Individuals. Journal of Virology, 2012, 86, 13281-13294.	1.5	45
51	Reply to "Nuclear Export Signal and Immunodominant CD8+T Cell Epitope in Influenza A Virus Matrix Protein 1". Journal of Virology, 2012, 86, 10259-10260.	1.5	1
52	Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes. Molecular Immunology, 2011, 49, 395-401.	1.0	29
53	An unexpected similarity between antibiotic-resistant NDM-1 and beta-lactamase II from Erythrobacter litoralis. Protein and Cell, 2011, 2, 250-258.	4.8	34
54	Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Experimental Biology and Medicine, 2011, 236, 253-267.	1.1	35